news
IXI™ is IXICO’s proprietary, AI-enabled neuroimaging technology platform for precision medicine, purpose-built to drive clinical trial imaging and biomarker science insights in neurological disease research.
The Platform, combined with IXICO's expert clinical trial operations, helps accelerate decision-making in clinical research and maximise the potential of drug development programmes.
Start your day with breakfast, networking and expert perspectives on the future of amyloid assessment.
Featuring lightning talks from Mike Weiner, UCSF; Tobias Bittner, Roche; and Robin Wolz, IXICO, covering screening, multimodal assessment and the opportunities for AI.
Wednesday 18 Nov | 07.00 - 08.20 | Salon A
IXICO has built a global reputation as a leading end-to-end Imaging Contract Research Organisation (iCRO), expertly managing and analysing neurological clinical trials.
The Company is a key part of the global neurological disease research community, with a 20-year proven track record in the biopharmaceutical industry, working with leading pharma companies, innovative biotechs, scientific consortia, and non-profit organisations.
The IXI™ Platform is tailor-made for neurological diseases, reliably managing global clinical trial data, precisely reading radiological scans, and measuring key imaging biomarkers linked to the identification, progression, and treatment of conditions such as Alzheimer’s, Huntington’s, and Parkinson’s disease.
